S African variant may 'break through' Pfizer jab, but vaccine highly effective, Israeli study says | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Friday
July 25, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
FRIDAY, JULY 25, 2025
S African variant may 'break through' Pfizer jab, but vaccine highly effective, Israeli study says

Coronavirus chronicle

Reuters
19 April, 2021, 03:50 pm
Last modified: 19 April, 2021, 03:57 pm

Related News

  • Pfizer expects to hike US Covid vaccine price to $110-$130 per dose
  • US donates 10 million more Pfizer Covid shots to Bangladesh
  • Pfizer says 3 Covid shots protect children under 5
  • Pfizer eyes Covid vaccine for all variants before 2023
  • Pfizer-BioNTech seek US approval of second Covid booster for 65+

S African variant may 'break through' Pfizer jab, but vaccine highly effective, Israeli study says

The South African variant, B.1.351, was found to make up about 1% of all the Covid-19 cases across all the people studied

Reuters
19 April, 2021, 03:50 pm
Last modified: 19 April, 2021, 03:57 pm
FILE PHOTO: Vials labelled "COVID-19 Coronavirus Vaccine" and a syringe are seen in front of the Pfizer logo in this illustration taken February 9, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
FILE PHOTO: Vials labelled "COVID-19 Coronavirus Vaccine" and a syringe are seen in front of the Pfizer logo in this illustration taken February 9, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

The coronavirus variant discovered in South Africa can break through the protection provided by Pfizer Inc and BioNTech's Covid-19 vaccine to some extent, a real-world data study in Israel found. However, the variant's prevalence in Israel is very low and the vaccine remains highly effective.

The study was released on the medRxiv pre-print site on April 9 and has not been peer reviewed. It compared almost 400 people who had tested positive for Covid-19, after they received one or two doses of the vaccine, against the same number of unvaccinated patients with the disease.

It matched age and gender, among other characteristics.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

The South African variant, B.1.351, was found to make up about 1% of all the Covid-19 cases across all the people studied, according to the study by Tel Aviv University and Israel's largest healthcare provider, Clalit.

But among patients who had received two doses of the vaccine, the variant's prevalence rate was eight times higher than those unvaccinated - 5.4% versus 0.7%.

This suggests the vaccine is less effective against the South African variant, compared with the original coronavirus and a variant first identified in Britain that has come to comprise nearly all Covid-19 cases in Israel, the researchers said.

The researchers said the study was not intended to assess overall vaccine effectiveness against any variant, since it only looked at people who had already tested positive for Covid-19, not at overall infection rates.

Separate real-world Israeli studies on the vaccine's overall effectiveness, including by Clalit, have shown the Pfizer shot to be more than 90% effective.

"We found a disproportionately higher rate of the South African variant among people vaccinated with a second dose, compared to the unvaccinated group. This means that the South African variant is able, to some extent, to break through the vaccine's protection," said Tel Aviv University's Adi Stern.

In an update to the study posted on April 16, the researchers noted that within the group of people who received two doses, which comprised eight people, all of the B.1.351 infections occurred within a week to 13 days after the second shot. None of them tested positive for it 14 days or more after the second dose.

"This may imply that there is a short window of susceptibility to B.1.351 infection limited to the immediate two weeks after the second dose – but we cannot be confident that this is indeed the case," Stern and Clalit's Ran Balicer said in an email to Reuters on Sunday.

The researchers cautioned, though, that the study only had a small sample size of people infected with the South African variant because of its rarity in Israel.

"The B.1.351 incidence in Israel to-date remains low and vaccine effectiveness remains high among those fully vaccinated," the study said.

Pfizer declined to comment on the Israeli study. Pfizer and BioNTech said on April 1 that their vaccine was around 91% effective at preventing Covid-19, citing updated trial data that included participants inoculated for up to six months.

They have been testing a third dose of their shot as a booster, and have said they could modify the shot to specifically address new variants if needed.

In respect to the South African variant, they said that among a group of 800 study volunteers in South Africa, where B.1.351 is widespread, there were nine cases of Covid-19, all of which occurred among participants who got the placebo. Of those nine cases, six were among individuals infected with the South African variant.

Some previous studies have indicated that the Pfizer/BioNTech shot was less potent against the B.1.351 variant than against other variants of the coronavirus, but still offered a powerful defence.

While the results of the study may cause concern, the low prevalence of the South African strain was encouraging, according to Stern.

"Even if the South African variant does break through the vaccine's protection, it has not spread widely through the population," said Stern, adding that the British variant may be "blocking" the spread of the South African strain.

More than half of Israel's 9.3 million population has received both Pfizer doses. Israel has largely reopened its economy in recent weeks while the pandemic appears to be receding with a sharp drop in infections and hospitalizations.

Top News

Pfizer Covid-19 Vaccine / Covid-19 New Variant

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Infographics: TBS
    Inflated rents, ghost floors, Tk220cr advance: How Premier Bank funds lined Iqbal family’s pocket
  • File photo of a new NBR office in Agargaon, Dhaka. Photo: UNB
    NBR chief directs customs officials to clear consignments within a day
  • Ahsan H Mansur. TBS sketch
    True ownership of S Alam loans, shares under fake names to be proven thru state witnesses: BB governor

MOST VIEWED

  • Representational image/Reuters
    Dollar gets upward push as BB buys $10m more in auction at even higher rate
  •  ABM Khairul Haque. File Photo: Collected
    Former chief justice Khairul Haque detained
  • File photo of Bangladesh Bank. Photo: TBS
    Governor Mansur orders withdrawal of BB dress code after directive draws criticism
  • Representational image. Photo: Collected
    Tariff talks: Bangladesh, US set for crucial virtual meeting on 29 July
  • Mehreen Ahmed speaking to media on 11 July 2025. Photo: Collected
    Court disposes of Dhaka girl's case against parents seeking 'protection from abuse'
  • Hasina and Taposh in an event in 2020. Photo: Collected
    Al Jazeera investigation: Hasina, in call with Taposh, talks using helicopter to shoot, crush protesters in July uprising

Related News

  • Pfizer expects to hike US Covid vaccine price to $110-$130 per dose
  • US donates 10 million more Pfizer Covid shots to Bangladesh
  • Pfizer says 3 Covid shots protect children under 5
  • Pfizer eyes Covid vaccine for all variants before 2023
  • Pfizer-BioNTech seek US approval of second Covid booster for 65+

Features

Illustration: TBS

The future of medicine: How innovations will catalyse quantum leaps in healthcare

13h | The Big Picture
Photo: Collected

24 July: More than 1400 arrested, 3 missing coordinators found

1d | Panorama
Photo: Mehedi Hasan/TBS

Aggrieved nation left with questions as citizens rally to help at burn institute

2d | Panorama
Photo: Mehedi Hasan/TBS

Mourning turns into outrage as Milestone students seek truth and justice

2d | Panorama

More Videos from TBS

There are many more examples of trials of Chief Justices in the world.

There are many more examples of trials of Chief Justices in the world.

11h | TBS Today
Why is there a massive conflict between Thailand and Cambodia?

Why is there a massive conflict between Thailand and Cambodia?

12h | TBS News Updates
Former Chief Justice ABM Khairul Haque in prison

Former Chief Justice ABM Khairul Haque in prison

12h | TBS Today
The Nvidia Chip Deal Trades Away the United States’ AI Advantage

The Nvidia Chip Deal Trades Away the United States’ AI Advantage

12h | Videos
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net